Medical Cannabis Studies


• addiction (10)

• alzheimers/dementia (14)

• amyotrophic-lateral-sclerosis-als-lou-gehrigs (2)

• antibacterial (6)

• antioxidant (8)

• antiprion (1)

• anxiety (10)

• appetite (4)

• arthritis (4)

• asthma (1)

• attention-deficit-hyperactivity-disorder-adhd (5)

• autism (11)

• autoimmune (3)


• batten-disease (6)

• benefits (9)

• breast-cancer (7)


• cancer (94)

• cannabidiol-cbd (8)

• cardiovascular (8)

• cb1-receptor (8)

• cb2-receptor (9)

• cellular-function (4)

• cerebral-palsy (1)

• cognition (2)

• colon-cancer (8)


• d9-tetrahydrocannabinol-thc (4)

• d9-tetrahydrocannabinolic-acid-thca (1)

• diabetes (4)

• drug-interactions (2)


• emesis (6)

• endocannabinoid-system-ecs (45)

• endocrine-system (3)

• epilepsy (30)


• fibromyalgia (2)

• fibrosis (1)


• gastrointestinal-disease (6)

• general (20)

• glaucoma (1)

• glioblastoma (1)

• glioma (9)


• health-care (1)

• hiv (7)

• huntingtons-disease (1)


• immune-function (8)

• infant-development (1)

• inflammation (9)

• ischemia (3)


• krabbe-disease (4)


• liver (2)

• lung-cancer (2)

• lupus (1)


• memory (3)

• mental-illness (14)

• migraine (1)

• mitochondria (1)

• multiple-sclerosis (15)


• national-institute-on-drug-abuse-nida (1)

• nausea (1)

• nervous-system (4)

• neuro-protective-and-neuro-generative (7)


• pain (29)

• pancreatitis (1)

• prostate-cancer (2)


• schizophrenia (2)

• skin (1)

• sports (3)


• thc (1)

• therapeutic (1)

• traumatic-brain-injury-tbi (1)

• View All (505)
  • The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease. (2017)

    Alzheimer’s disease (AD) is the most common neurodegenerative disorder, characterized by a progressive loss of cognition. The present review was focused on presenting a brief introduction to (AD) biology and current treatment options before outlining comprehensively phytocannabinoid cannabidiol (CBD) biology and pharmacology, followed by in-vitro and in-vivo evidence for the therapeutic potential of (CBD). View study

  • The use of different treatment for incoordination of limb movement (ataxia) or tremor in people with multiple sclerosis (2007)

    The absolute and comparative efficacy and tolerability of pharmacotherapies to treat ataxia in multiple sclerosis are poorly documented and can not be prescribed. Neurosurgery and neurorehabilitation studies showed promising results in the treatment of ataxia in MS. View study

  • The Use of Medical Cannabis with Other Medications: A Review of Safety and Guidelines [Internet] (2017)

    Marijuana or cannabis is a material similar to tobacco obtained from flowers, fruit cups and leaves of the cannabis plant. The purpose of this report was to review the clinical evidence and evidence-based guidelines regarding the safety and interaction of the use of medicinal cannabis with other medications. View study

  • The Use of Medical Marijuana in Cancer. (2016)

    The use of medical marijuana in the treatment of cancer presents a dilemma for both patients and doctors. The purpose of this review was to address the current state of the research, including potential indications, risks and adverse effects, preliminary data on anticancer effects, as well as legal and quality issues. View study

  • Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis (2003)

    Theiler’s virus infection of the CNS induces an immune-mediated demyelinating disease in susceptible mouse strains and serves as a relevant infection model for human multiple sclerosis (MS). The objective of the present research was to study the therapeutic action of cannabinoids in a murine model of multiple sclerosis. By using Theiler’s murine encephalomyelitis virus model, we report here that the treatment with the synthetic cannabinoids WIN 55,212-2, ACEA and JWH-015 during the established disease significantly improved the neurological deficits in a lasting manner. View study

  • Therapeutic aspects of cannabis and cannabinoids (2014)

    View study

  • Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients. (2018)

    The objective of this research was to review the benefits and risks of cannabis use, with emphasis on the processes of otorhinolaryngological diseases, as well as to define and review the endocannabinoid signaling system (ESS) and review the state and federal regulations for the use of cannabis. Research on cannabis modulators and ESS. View study

  • Therapeutic Potential of Cannabinoids in CNS Disease (2003)

    The present research aimed to highlight recent advances in the understanding of the endocannabinoid system and indicates disorders of the central nervous system (CNS) that may benefit from the therapeutic effects of cannabinoid treatment. View study

  • Therapeutic potential of medicinal marijuana: an educational primer for health care professionals (2018)

    With the proposal to legalize marijuana in July 2018 in Canada through the Cannabis Act, a thorough critical analysis of current trials on the efficacy of medical marijuana (MM) as a treatment option is necessary. The purpose of this review is to complement the Health Canada document by providing physicians with a critical but concise update on the recent advances made regarding the efficacy of MM as a potential therapeutic option. View study

  • Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke (2010)

    This research aims to discuss the therapeutic possibility of cannabidiol (CBD), as a cerebroprotective agent, highlighting pharmacological advances, new mechanisms and the therapeutic time window of the (CBD) in ischemic stroke View study

  • Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis (2008)

    The present research focused on the use of cannabis as a therapeutic agent to treat nausea and vomiting induced by chemotherapy in cancer patients View study

  • Therapeutical use of the cannabinoids in psychiatry ()

    The results found in this study show that cannabidiol has therapeutic potential with antipsychotic, anxiolytic and antidepressant properties, as well as being effective under other conditions. Cannabinoids may be of great therapeutic interest for psychiatry. View study